Dr. Suman Jayadev
Claim this profileUniversity of Washington
Studies Dementia
Studies Alzheimer's Disease
6 reported clinical trials
11 drugs studied
Area of expertise
1Dementia
APP positive
PSEN1 positive
PSEN2 positive
2Alzheimer's Disease
APP positive
PSEN1 positive
PSEN2 positive
Affiliated Hospitals
Clinical Trials Suman Jayadev is currently running
Gantenerumab
for Alzheimer's Disease
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Remternetug
for Alzheimer's Disease
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting0 awards Phase 2 & 32 criteria
More about Suman Jayadev
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Suman Jayadev has experience with
- E2814
- Gantenerumab
- Lecanemab
- Solanezumab
- Placebo
- PTC518
Breakdown of trials Suman Jayadev has run
Dementia
Alzheimer's Disease
Huntington's Disease
Alzheimer's
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Suman Jayadev specialize in?
Suman Jayadev focuses on Dementia and Alzheimer's Disease. In particular, much of their work with Dementia has involved APP positive patients, or patients who are PSEN1 positive.
Is Suman Jayadev currently recruiting for clinical trials?
Yes, Suman Jayadev is currently recruiting for 4 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Suman Jayadev has studied deeply?
Yes, Suman Jayadev has studied treatments such as E2814, Gantenerumab, Lecanemab.
What is the best way to schedule an appointment with Suman Jayadev?
Apply for one of the trials that Suman Jayadev is conducting.
What is the office address of Suman Jayadev?
The office of Suman Jayadev is located at: University of Washington, Seattle, Washington 98195 United States. This is the address for their practice at the University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.